Citigroup Inc. and its affiliates have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 5.01% in Puretech Health Plc. The filing, which details ownership of 12,004,514 ordinary shares, was made in accordance with SEC rules 13d-1(b), (c), and (d) and amendments thereto filed pursuant to rule 13d-2. The entities involved in the filing include Citigroup Global Markets Limited, Citigroup Global Markets Holdings Bahamas Limited, Citigroup Financial Products Inc., Citigroup Global Markets Holdings Inc., and Citigroup Inc. The filing indicates that the shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The principal business offices for the entities are located in London, England, Nassau, Bahamas, and New York, NY.

Citigroup Inc. and its affiliates have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 5.01% in Puretech Health Plc. The filing, which details ownership of 12,004,514 ordinary shares, was made in accordance with SEC rules 13d-1(b), (c), and (d) and amendments thereto filed pursuant to rule 13d-2. The entities involved in the filing include Citigroup Global Markets Limited, Citigroup Global Markets Holdings Bahamas Limited, Citigroup Financial Products Inc., Citigroup Global Markets Holdings Inc., and Citigroup Inc. The filing indicates that the shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The principal business offices for the entities are located in London, England, Nassau, Bahamas, and New York, NY.